Peptide questions · Amycretin
Amycretin side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for amycretin are nausea, vomiting and diarrhea, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: amycretin has no label: it is still in trials.
What is commonly reported with amycretin
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Decreased appetite | 9: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 5 more |

Model. Individual results vary.
Which amycretin side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on amycretin’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is amycretin’s own.
What the amycretin safety notes say
The library’s safety note
Amycretin has no label: it is still in trials. In the phase 1b/2a obesity trial, the most common side effects were GI, mostly mild to moderate and gone by the end of the study; the authors called the GI rates high but similar to early studies of other GLP-1 and amylin drugs. In the 36-week phase 2 trial in type 2 diabetes, most side effects were GI and mild to moderate, and serious events were spread across doses and placebo (8% overall, no deaths). It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
The library’s interaction note
No interaction studies have been published. GLP-1 and amylin both slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself (and already carries an amylin signal), so it is not stacked with another GLP-1 or with cagrilintide. In a kidney study, exposure was 13% to 35% higher with reduced kidney function, which the authors judged not to need a dose change. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the amycretin reports come from
The library rates the evidence on amycretin as moderate: animal studies plus some human data.
Of the library’s 8 research notes on amycretin, 3 rest on randomized trials, 4 on clinical data and 1 on community reports.
Our 6 study pages on amycretin: 4 randomized trials, 1 clinical trial and 1 animal study (mice and rats).
So amycretin has controlled trials in people to set its listed effects against.
What our amycretin study pages report on safety
Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeks
Randomized trial, human, 2026: Stomach and gut side effects were the most common, seen in 26% of the 6 mg arm, 41% of the 25 mg arm, 47% of the 50 mg arm and 23% of the placebo arm. Serious adverse events occurred in 7 participants, all taking amycretin (2, 2 and 3 across the dose arms), none on placebo, and nobody died.
Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetes
Randomized trial, human, 2026: Most side effects involved the gut and were mild to moderate. Serious adverse events occurred in 21 (8%) of 261 treated participants, 3 of them on placebo, and no one died.
Amycretin: similar drug exposure with kidney impairment in phase 1
Clinical trial, human, 2026: Side effects that appeared during the study were reported in 30 people (71.4%); none were serious or severe, most were mild, and most often they were gastrointestinal (stomach and gut). The researchers concluded that kidney impairment did not appear to have a clinically relevant effect on the drug's blood levels or safety, and that dose adjustment did not seem warranted for these people.
Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trial
Randomized trial, human, 2025: Stomach and bowel complaints led the side effect list; most were rated mild or moderate and had gone away by the study's end. A large share of people left the study, many of them for reasons other than side effects.
Amycretin: side effects all mild or moderate in first human trial
Randomized trial, human, 2025: Across all parts, 89 (62%) of 144 people had at least one adverse event, meaning any health problem that came up during the study, with 364 events in total. This was a small, early safety trial at a single site, lasting at most 12 weeks of treatment.
Questions people ask
What are the side effects of amycretin?
The side effects most commonly reported for amycretin are nausea, vomiting and diarrhea, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Do amycretin’s side effects come from human studies?
The library rates the evidence on amycretin as moderate, and the library’s evidence on it includes controlled trials in people.
Which amycretin side effects are its own?
None: each effect the library lists for amycretin is listed for at least one other metabolic & GLP-1 compound too.
Does amycretin interact with other medicines?
The library’s interaction note on amycretin begins: No interaction studies have been published.